UA117571C2 - Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності - Google Patents

Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності

Info

Publication number
UA117571C2
UA117571C2 UAA201505170A UAA201505170A UA117571C2 UA 117571 C2 UA117571 C2 UA 117571C2 UA A201505170 A UAA201505170 A UA A201505170A UA A201505170 A UAA201505170 A UA A201505170A UA 117571 C2 UA117571 C2 UA 117571C2
Authority
UA
Ukraine
Prior art keywords
blood pressure
methods
heart failure
controlling blood
dyspnea
Prior art date
Application number
UAA201505170A
Other languages
English (en)
Inventor
Едвард Сі. мол. Спіндлер
Лоретта М. Ітрі
Грегорі Чарльз Вілльямс
Мінг-йі Ху
Original Assignee
Чіесі Фармацеутічі С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чіесі Фармацеутічі С.П.А. filed Critical Чіесі Фармацеутічі С.П.А.
Publication of UA117571C2 publication Critical patent/UA117571C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується способу зниження диспное у пацієнтів, що хворіють або схильні до гострої серцевої недостатності, що включає введення ефективної кількості фармацевтичної композиції, що містить дигідропіридинову сполуку з коротким періодом дії, таку як клевідипін.
UAA201505170A 2012-10-26 2013-10-26 Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності UA117571C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (1)

Publication Number Publication Date
UA117571C2 true UA117571C2 (uk) 2018-08-27

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201505170A UA117571C2 (uk) 2012-10-26 2013-10-26 Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності

Country Status (18)

Country Link
US (1) US10881645B2 (uk)
EP (1) EP2925128B1 (uk)
JP (2) JP6329957B2 (uk)
KR (1) KR102299073B1 (uk)
CN (2) CN110840890A (uk)
AU (1) AU2013334081B2 (uk)
BR (1) BR112015009291B1 (uk)
CA (1) CA2889584C (uk)
EA (1) EA030354B1 (uk)
ES (1) ES2671639T3 (uk)
IL (1) IL238462A0 (uk)
MX (1) MX359768B (uk)
NZ (1) NZ708511A (uk)
PL (1) PL2925128T3 (uk)
TR (1) TR201807636T4 (uk)
UA (1) UA117571C2 (uk)
WO (1) WO2014066870A1 (uk)
ZA (1) ZA201503741B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2947486C (en) 2014-05-19 2023-09-26 The Medicines Company Clevidipine nanoparticles and pharmaceutical compositions thereof
CN112118846B (zh) * 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
US9925265B2 (en) * 2009-11-11 2018-03-27 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
PL2320740T3 (pl) 2008-08-01 2014-09-30 The Medicines Co Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń
WO2010014234A1 (en) 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for stabilizing the same
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
PT2627173E (pt) * 2010-10-12 2015-07-24 Medicines Co Formulações de clevidipina em emulsão contendo agentes antimicrobianos
CN103781479A (zh) 2011-04-01 2014-05-07 医药公司 用于减轻中风损害的短效二氢吡啶（氯维地平）

Also Published As

Publication number Publication date
CN104968199A (zh) 2015-10-07
CN110840890A (zh) 2020-02-28
CA2889584A1 (en) 2014-05-01
MX2015005341A (es) 2016-05-24
EA201590825A1 (ru) 2015-09-30
ES2671639T3 (es) 2018-06-07
EP2925128A4 (en) 2016-06-08
MX359768B (es) 2018-10-10
IL238462A0 (en) 2015-06-30
US20140121247A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
WO2014066870A1 (en) 2014-05-01
JP6329957B2 (ja) 2018-05-23
AU2013334081A1 (en) 2015-06-11
JP2018065875A (ja) 2018-04-26
US10881645B2 (en) 2021-01-05
KR20150104084A (ko) 2015-09-14
AU2013334081B2 (en) 2017-05-18
ZA201503741B (en) 2022-09-28
BR112015009291B1 (pt) 2021-03-16
NZ708511A (en) 2018-11-30
CA2889584C (en) 2018-08-14
EP2925128B1 (en) 2018-04-11
EP2925128A1 (en) 2015-10-07
PL2925128T3 (pl) 2018-10-31
TR201807636T4 (tr) 2018-06-21
KR102299073B1 (ko) 2021-09-09
BR112015009291A2 (pt) 2017-07-04
EA030354B1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
EP4233861A3 (en) Compositions for treatment of essential tremor
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2022004012A (es) Solucion de bloqueo de cateter y terapia de bloqueo de cateter.
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
NZ714963A (en) Compositions and methods for treating anemia
TN2011000217A1 (en) Pirfenidone treatment for patients with atypical liver fuction
PH12016501357A1 (en) Pharmaceutical preparation containing pyridylamino acetic acid compound
JP2017501154A5 (uk)
UA105191C2 (uk) Лікування пірфенідоном пацієнтів з атиповою функцією печінки
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
NZ751972A (en) Treatment of prurigo nodularis
WO2010107251A3 (ko) 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물
MY179794A (en) Compound composition for inhalation used for treating asthma
RU2011123367A (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
WO2013058627A3 (ko) 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
PH12016500716B1 (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
Morales Bradycardia and hypotension: case report
NZ600486A (en) Pirfenidone treatment for patients with atypical liver function